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ABSTRACT (239 words) 31 
Aims: Darapladib, a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), has not reduced 32 
risk of cardiovascular disease outcomes in recent randomized trials. We aimed to test whether Lp-PLA2 enzyme 33 
activity is causally relevant to coronary heart disease (CHD).  34 
Methods: In 72,657 patients with CHD and 110,218 controls in 23 epidemiological studies, we genotyped five 35 
functional variants, four rare loss-of-function mutations (c.109+2T>C[rs142974898], Arg82His[rs144983904], 36 
Val279Phe[rs76863441], Gln287Ter[rs140020965]) and one common modest-impact variant 37 
(Val379Ala[rs1051931]) in PLA2G7, the gene encoding Lp-PLA2.. We supplemented de-novo genotyping with 38 
information on a further 45,823 CHD patients and 88,680 controls in publicly available databases and other 39 
previous studies. We conducted a systematic review of randomized trials to compare effects of darapladib 40 
treatment on soluble Lp-PLA2 activity, conventional cardiovascular risk factors, and CHD risk with 41 
corresponding effects of Lp-PLA2-lowering alleles.  42 
Results: Lp-PLA2 activity was decreased by 64% (p=2.4×10-25) with carriage of any of the four loss-of-function 43 
variants, by 45% (p<10-300) for every allele inherited at Val279Phe, and by 2.7% (p=1.9×10-12) for every allele 44 
inherited at Val379Ala. Darapladib 160mg once-daily reduced Lp-PLA2 activity by 65% (p<10-300). Causal risk 45 
ratios for CHD per 65% lower Lp-PLA2 activity were: 0.95 (0.88-1.03) with Val279Phe; 0.92 (0.74-1.16) with 46 
carriage of any loss-of-function variant; 1.01 (0.68-1.51) with Val379Ala; and 0.95 (0.89-1.02) with darapladib 47 
treatment. 48 
Conclusions: In a powerful large-scale human genetic study, none of a series of Lp-PLA2–lowering alleles was 49 
related to CHD risk, suggesting that Lp-PLA2 is unlikely to be a causal risk factor.  50 
51 
KEY WORDS:  Human genetics, target validation, coronary heart disease, Lipoprotein-associated 52 
phospholipase A2, darapladib 53 
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ABBREVIATIONS 54 
CHD = Coronary Heart Disease 55 
CI = Confidence Interval 56 
HDL = High-density lipoprotein 57 
LDL = Low-density lipoprotein 58 
Lp-PLA2 = Lipoprotein-associated phospholipase A259 
MI = Myocardial infarction 60 
SD = Standard deviation 61 
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INTRODUCTION 66 
Lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme expressed by inflammatory cells in 67 
atherosclerotic plaques, is carried in the circulation bound predominantly to low-density-lipoprotein (LDL)1,2. 68 
Lp-PLA2 (also called platelet-activating factor acetyl hydrolase) hydrolyzes oxidized phospholipids to yield pro-69 
inflammatory products implicated in endothelial dysfunction, plaque inflammation, and formation of necrotic 70 
core in plaque1. Observational3 and experimental studies in humans and animals have suggested that Lp-PLA2 71 
could be a valid therapeutic target, postulating this enzyme to link oxidative modification of LDL and 72 
development of inflammatory responses to arterial intima1. Previous studies have investigated genetic variants 73 
altering Lp-PLA2 function in relation to coronary heart disease (CHD) risk4,5. However, these studies have 74 
generally yielded inconclusive, or conflicting results4,5, perhaps due to limited statistical power and due to 75 
limited knowledge about variants altering Lp-PLA2 function (e.g., previous studies have been able to consider 76 
only one loss-of-function variant in PLA2G7, the gene encoding Lp-PLA2). 77 
However, two phase 3 randomized trials of darapladib, a potent inhibitor of Lp-PLA2 activity, have not shown 78 
reductions in cardiovascular risk6,7. These results could, at least in part, have been due to features of the trials. 79 
One of the phase 3 trials was restricted to patients recently hospitalized with acute coronary syndromes6, yet 80 
many cardiovascular events occurring early after acute coronary syndromes may relate to thrombotic 81 
mechanisms and not be modifiable through Lp-PLA2 inhibition. Trials used statins as background therapy, so 82 
any Lp-PLA2 inhibition achieved with statins could have reduced any incremental benefits of darapladib. Trials 83 
could not assess the effects of prolonged Lp-PLA2 inhibition because they recorded only about 3-4 years of 84 
median follow-up6,7. 85 
An alternative explanation is that darapladib did not reduce cardiovascular risk because Lp-PLA2 is not a causal 86 
risk factor in cardiovascular disease. We tested this possibility by investigating natural loss of Lp-PLA2 activity. 87 
Studies of Lp-PLA2–lowering alleles should complement randomized trials of darapladib because genotypes are 88 
fixed at conception, avoiding potential distorting effects of pre-existing disease and medication usage. 89 
Furthermore, Lp-PLA2–lowering alleles should produce lifelong, rather than shorter-term, Lp-PLA2 inhibition.  90 
In over 260,000 participants of European, South Asian, or East Asian ancestries, we studied five functional 91 
variants in PLA2G7. We compared effects of Lp-PLA2-lowering alleles on soluble Lp-PLA2 activity, 92 
conventional cardiovascular risk factors, and CHD risk with corresponding effects of darapladib, using results 93 
from randomized trials.  94 
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METHODS 95 
Study design 96 
Figure 1 summarises the study approach. Table 1 provides definitions and sources of data used. First, we 97 
identified four loss-of-function mutations and one missense variant in PLA2G7 suggested by previous 98 
experimental and bioinformatics studies, thereby developing an allelic series for Lp-PLA2 activity. Second, we 99 
assessed associations of these variants ─ both singly and in combination ─ with soluble Lp-PLA2 activity, 100 
conventional cardiovascular risk factors, and CHD risk in people of European, South Asian, or East Asian 101 
continental ancestries. Third, we compared associations of Lp-PLA2–lowering alleles with the aforementioned 102 
traits and CHD risk with the effects of darapladib treatment through a systematic review of randomized trials.  103 
Genetic variants 104 
We defined loss-of-function variants as non-synonymous variants with in vitro or in vivo evidence 105 
demonstrating complete lack of Lp-PLA2 activity or sequence changes expected to abolish Lp-PLA2 function 106 
(e.g., nonsense variants or mutations in essential splice sites). We selected variants through a systematic search 107 
for loss-of-function variants using the UniProt database8, the Exome Aggregation Consortium database 108 
(Cambridge, MA, USA; URL: http://exac.broadinstitute.org; [accessed November 2014])9, studies of site-109 
directed mutagenesis10-12 and results from targeted gene sequencing13. Among the full set of variants identified 110 
(eTable1), we selected the following variants that could be detected in the 1000 Genomes14 or the Exome 111 
sequencing15 projects (and, hence, potentially studied at the population level): the splice site mutation 112 
109+2T>C (rs142974898); two non-synonymous variants ─ Arg82His (rs144983904) and Val279Phe 113 
(rs76863441); and the nonsense variant Gln287Ter (rs140020965). These loss-of-function variants are rare in 114 
European and South Asian ancestry populations, whereas carriage of 279Phe is common in East Asian ancestry 115 
populations and abolition of Lp-PLA2 activity is well documented16. Additionally, we studied Val379Ala 116 
(rs1051931), a functional variant common in European ancestry populations, which lowers Lp-PLA2 activity 117 
only modestly10,17, in contrast with the substantial much stronger Lp-PLA2–lowering achieved by the loss-of-118 
function variants described above.  119 
Samples and data for genetic studies  120 
We aimed to maximise study power and comprehensiveness by using the following complementary approaches 121 
to generate new data on, as well as to collate systematically existing relevant information about, the PLA2G7 122 
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variants mentioned above: (1) we conducted de-novo genotyping for 72,657 CHD patients and 110,218 controls 123 
(the majority of whom also had information available on some cardiovascular risk factors); (2) we accessed non-124 
overlapping summary-level data from the only known global genetics consortium of CHD18, yielding 125 
information on a further 35,735 CHD patients and 73,481 controls; (3) we conducted a systematic review 126 
(supplemented by provision of tabular data from each study investigator) of published East Asian CHD studies 127 
of Val279Phe because these studies were not represented in the global CHD consortium, yielding information 128 
on a further 10,088 CHD cases and 15,199 controls; (4) we accessed summary-level data from the largest 129 
available global genetics consortium on each of several relevant cardiovascular risk factors (eg, Lp-PLA2 130 
activity, conventional lipids, blood pressure), yielding information on 489,045 participants. Each of these 131 
sources of information is summarised below and in Table 1, with a key in Table 1’s legend denoting the level 132 
of data detail available for each source (e.g., individual-participant data vs. tabular study-level results).  133 
Coronary heart disease outcomes For CHD outcomes, we had access to data for a total of 92,995 patients and 134 
162,228 controls. For 182,875 of these participants (72,657 CHD patients, 110,218 controls), we did de-novo 135 
genotyping of the four loss-of-function variants (c.109+2T>C, Arg82His, Val279Phe, Gln287Ter) and 136 
Val379Ala using customized Exome arrays (Illumina, California, USA) by technicians masked to the 137 
phenotypic status of the participants’ samples. For 35,829 CHD cases, 44,948 controls in eight studies, we had 138 
access to individual-participant data. The eight studies were: the Bangladesh Risk of Acute Vascular Events 139 
Study (BRAVE)19, Copenhagen City Heart Study (CCHS)20, Copenhagen Ischemic Heart Disease/Copenhagen 140 
General Population Study (CIHDS/CGPS)20, European Prospective Investigation into Cancer and Nutrition-141 
Cardiovascular Disease Study (EPIC-CVD)21, MONICA Risk, Genetics, Archiving, and Monograph 142 
(MORGAM) study22,23, Pakistan Risk of Myocardial Infarction Study (PROMIS)24, Pravastatin in elderly 143 
individuals at risk of vascular disease (PROSPER) trial25  and the West of Scotland Coronary Prevention Study 144 
(WOSCOPS)26 (these eight studies are collectively called the “CHD Exome+ consortium”). For 15 additional 145 
studies (collectively called the “MICAD consortium”), we used similar genotyping methods to those described 146 
above but did not genotype c.109+2T>C and had access only to study-level data. We supplemented de-novo 147 
data on Val379Ala with non-overlapping consortium-level results from a further 35,735 CHD patients and 148 
73,481 controls in the transatlantic Coronary Artery Disease Genome-wide Replication and Meta-analysis 149 
(CARDIoGRAM)27 and Coronary Artery Disease Genetics (C4D)28 consortia (Table 1). We obtained tabular 150 
data on Val279Phe from seven East Asian studies involving a total of 10,088 CHD cases and 15,199 controls, 151 
identified through systematic review (eTable 5 and Supplement). About 90% of CHD patients in our genetic 152 
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analysis had myocardial infarction or other major acute coronary events; the remainder had angiographic 153 
evidence alone (eg, >50% coronary stenosis; eTables 2 & 5). 154 
Lp-PLA2 activity For 13,835 participants, we had information on functional variants in PLA2G7 and Lp-PLA2 155 
activity, using data from de-novo genotyping in MORGAM22,23 and PROSPER25, supplemented by published 156 
data from the CHARGE Consortium (ie, from the Atherosclerosis Risk in Communities [ARIC] Study29, 157 
Cardiovascular Health Study17, Framingham Heart Study17, and Rotterdam study17 ), and from 12 East Asian 158 
studies identified through the systematic review described above (Table 1, Supplement & eFigure1, eTables 159 
2-3). 160 
Conventional cardiovascular risk factors For 177,343 participants, we had information on functional variants in 161 
PLA2G7 and conventional cardiovascular risk factors and several other traits, including circulating 162 
concentrations of LDL-cholesterol, HDL-cholesterol, triglycerides, glucose, insulin, and C-reactive protein, and 163 
values of systolic and diastolic blood pressure, body-mass index, and estimated glomerular filtration rate. Again, 164 
we supplemented data from our de-novo genotyping, with information from existing global genetics consortia 165 
(Table 1, eTables 2-4).  166 
Randomized trials of darapladib 167 
To compare genetic associations with effects of pharmacological Lp-PLA2 inhibition, we conducted a 168 
systematic review to identify randomized placebo-controlled trials of darapladib that had reported on Lp-PLA2 169 
activity, conventional risk factors, and/or CHD events (Supplement). CHD events in the trials were defined as 170 
fatal CHD, MI or urgent revascularisation, as recorded in STABILITY (Stabilization of Atherosclerotic Plaque 171 
by Initiation of Darapladib Therapy) and in SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-172 
Thrombolysis in Myocardial Infarction 52)6,7. We pooled results across trials by fixed-effect inverse-variance 173 
weighted meta-analysis (eFigures 2&3; see Supplement for details of the methods used).  174 
Statistical methods 175 
We defined effect alleles as those associated with lower Lp-PLA2 activity and assumed an additive model. For 176 
participant-level data, we assessed associations of Lp-PLA2-lowering alleles with CHD using the genome-wide 177 
efficient mixed model analysis, an approach that models each genetic variant as a fixed-effect, but includes both 178 
fixed-effect and random-effects of genetic inheritance30 to account for population stratification and relatedness 179 
among participants (Supplement). The four rare loss-of-function variants were tested jointly within each study 180 
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by counting the number of loss-of-function alleles carried by each participant. Log odds ratios and standard 181 
errors were meta-analysed across studies using fixed-effect meta-analysis. For studies contributing only study-182 
level data, we performed a similar test by conducting a combined burden test across studies using the R package 183 
seqMeta v1.2 (http://cran.r-project.org/web/packages/seqMeta/).  184 
We calculated associations of Lp-PLA2-lowering alleles with soluble Lp-PLA2 activity and conventional risk 185 
factors using linear regression within each study, and then combined the regression coefficients using fixed-186 
effect meta-analysis. When data were missing, we used information on rs1805018 as a proxy for Val279Phe and 187 
information on rs7756935 or rs3799277 as proxies for Val379Ala (Supplement). To account for population 188 
stratification, we adjusted for the first principal component of ancestry (Supplement). We calculated risk ratios 189 
for CHD with decrements in Lp-PLA2 activity, dividing the log transformed risk ratio and confidence interval 190 
(CI) by the effect on Lp-PLA2 activity of the instrument (ie, the genetic variant)31. We investigated 191 
heterogeneity using the I2 statistic. We used Stata 13.1. 192 
193 
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RESULTS 194 
Of the 261,950 total participants in this analysis, we studied 195,715 individuals of European ancestry, 34,221 195 
individuals of South Asian ancestry, and 32,014 individuals of East Asian ancestry. In people of European or 196 
South Asian ancestry without CHD, the frequency of alleles in PLA2G7 that lower Lp-PLA2 activity was 197 
0.005% at c.109+2T>C, 0.04% at Arg82His, 0.04% at Val279Phe, and 0.025% at Gln287Ter (i.e., in aggregate, 198 
0.2% of the European or South Asian participants in the current study carried one of these loss-of-function 199 
alleles, although no one carried more than one of these variants), and about 80% at Val379Ala. In people of East 200 
Asian ancestry without CHD, the frequency of Val279Phe was about 15% and about 2% of the individuals were 201 
homozygous carriers of the 279Phe allele. 202 
Soluble Lp-PLA2 activity 203 
Compared with non-carriers, homozygote carriers of the 279Phe allele had 94% lower Lp-PLA2 activity (p<10-204 
300). For each 279Phe allele inherited, Lp-PLA2 activity decreased by 45% (1.59 SD, 95% CI: 1.61-1.57; p<10-205 
300). In Europeans who inherited any one of the four rare Lp-PLA2 loss-of-function alleles, Lp-PLA2 activity 206 
decreased by 64% (2.25 SD, 2.68-1.83; p=1.6×10-25). For each 379Ala allele inherited, Lp-PLA2 activity 207 
decreased by 2.7% (0.096 SD, 0.122-0.069; p=1.9×10-12). By comparison, 160mg once-daily darapladib reduced 208 
Lp-PLA2 activity by 65% (2.26 SD, 2.31-2.21; p<10-300). Study-level estimates are provided in eFigure 2. 209 
Cardiovascular risk factors 210 
None of the Lp-PLA2–related variants we studied was significantly associated with values of LDL-cholesterol, 211 
HDL-cholesterol, triglycerides, systolic or diastolic blood pressure, body-mass index, estimated glomerular 212 
filtration rate, glucose, insulin, and C-reactive protein (Figure 2). By comparison, in previous randomized 213 
placebo-controlled trials, darapladib did not significantly affect concentrations of LDL-cholesterol or log 214 
triglycerides, but could have slightly increased systolic blood pressure and HDL-cholesterol values and slightly 215 
decreased C-reactive protein concentration (Figure 2). 216 
217 
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Clinical CHD outcomes 218 
Compared to non-carriers, the odds ratio for CHD was 0.99 (0.95-1.03) in 279Phe heterozygotes, and 0.93 219 
(0.82–1.05) in 279Phe homozygotes (i.e. nearly complete loss of Lp-PLA2 function: Figure 3). For each loss-of-220 
function (279Phe) allele inherited, the odds ratio for CHD was 0.97 (0.91-1.02; I2=30%; PHeterogeneity=0.2). In 221 
Europeans and South Asians who inherited one of the four rare Lp-PLA2-loss-of-function alleles, the odds ratio 222 
for CHD was 0.92 (0.74-1.16; I2=0%; PHeterogeneity=0.8; Figure 3). For each 379Ala allele inherited, the odds 223 
ratio for CHD was 1.00 (0.98-1.02; I2=0.0%; PHeterogeneity=0.5; Figure 3). Study-level results are provided in 224 
eFigure 3. In sensitivity analyses, odds ratios with each loss-of-function variant were similar to the odds ratio 225 
that combined information across the four loss-of-function variants we studied. There was no evidence of 226 
heterogeneity in odds ratios between European and South Asian ancestry populations (eFigure 4).  227 
Genetic risk ratios for CHD per 65% lower Lp-PLA2 activity (i.e. the reduction achievable with darapladib 228 
treatment) were: 0.95 (0.88-1.03) with Val279Phe in East Asians; and 0.92 (0.74-1.16) with carriage of any one 229 
of the four rare variants studied in Europeans and South Asians; and 1.01 (0.68-1.51) with Val379Ala (Table 2). 230 
By comparison, the risk ratio for CHD with darapladib treatment (i.e. also per 65% lower Lp-PLA2 activity) was 231 
0.95 (0.89-1.02; Table 2). 232 
233 
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DISCUSSION 234 
In a large-scale analysis of human genetic data, we tested whether Lp-PLA2 enzyme activity is causally relevant 235 
to CHD by studying five functional alleles that produce widely differing (i.e., small, moderate, or large) degrees 236 
of reduction in Lp-PLA2 activity. We found that none was related to CHD risk, suggesting that Lp-PLA2 237 
enzyme activity is unlikely to be causally relevant to CHD, a conclusion concordant with results from two phase 238 
3 trials of a pharmacological Lp-PLA2 enzyme inhibitor  239 
Three features of our study merit comment. First, we studied almost 20 times more CHD patients than the 240 
previous largest study of loss-of-function PLA2G7 alleles, thereby providing the first robust genetic evaluation 241 
of effect sizes of Lp-PLA2 inhibition relevant to phase 3 trials such as relative risk reductions for CHD of 20%. 242 
For example, for the Val279Phe variant we had >99% power to detect a 20% risk reduction in CHD for a 65% 243 
genetic reduction in Lp-PLA2 activity (ie, an effect on Lp-PLA2 activity similar to that achieved by darapladib). 244 
Second, our study has provided the first investigation in CHD of a series of functional alleles that each reduce 245 
Lp-PLA2 function via different molecular mechanisms. Specifically, we studied five different Lp-PLA2-246 
lowering alleles: three of the alleles were coding variants that produced different amino acid substitutions; two 247 
of the alleles produced protein truncations (one due to a nonsense mutation; the other due to a splice-site 248 
mutation). Because we observed null and broadly concordant findings for CHD risk across these alleles that 249 
each changed the enzyme in a different way (and to a different extent), we can more confidently conclude there 250 
is no material cause-and-effect relationship. By contrast, when the initial phase 3 trial of darapladib was 251 
launched in 2008, only two of the five alleles we studied had yet been identified: data on Val379Ala, a weak 252 
effect missense variant, were inconclusive because CHD studies were under-powered32; data on Val279Phe, a 253 
loss-of-function variant, and CHD risk were sparse and restricted to East Asian populations.  254 
A third feature was our study’s analysis of large-scalesubstantial data from three different major ethnic groups: 255 
Europeans, South Asians, and East Asians. This ethnic diversity enhanced the generalisability of our results.  256 
Our study had potential limitations. To maximise comparability of CHD endpoints used in clinical trials with 257 
those used in human genetic studies, we restricted analysis of phase 3 darapladib trials to “major coronary 258 
events” and principally focused in human genetic studies on the cognate endpoints of myocardial infarction or 259 
other major acute coronary events (which constituted ~90% of the outcomes). Nevertheless, although the CHD 260 
definitions used in trials and genetic studies were similar, they were not identical.  261 
12 
It could be that cardioprotective benefits of Lp-PLA2 inhibition were obscured by pleiotropic effects of PLA2G7 262 
variants; for example, 279Phe is known to produce a misfolded version of Lp-PLA2 not secreted by cells, 263 
prompting suggestions that its carriage could produce “off-target” effects such as increased cell death33,34. 264 
However, because we found null associations between four other functional alleles in PLA2G7 and CHD, each 265 
of which operates via a different molecular mechanism, it argues against this explanation. On the other hand, it 266 
is possible that darapladib may have additional effects beyond  Lp-PLA2 inhibition. For example, darapladib 267 
may have had slight effects on CRP levels and systolic blood pressure, which we did not observe with the 268 
genetic variants.  269 
Lifelong genetic reductions in Lp-PLA2 could result in compensatory responses that increase CHD risk. 270 
However, this explanation seems unlikely because it would require any such compensation to apply similarly 271 
across alleles that produce widely differing degrees of reduction in Lp-PLA2 activity. Furthermore, any such 272 
compensation could not operate through known cardiovascular mechanisms because we observed no 273 
associations between Lp-PLA2-lowering alleles and several established and emerging cardiovascular risk 274 
factors.  275 
Soluble enzyme activity could be an imperfect indicator of the relevance of Lp-PLA2 to atherosclerotic plaques. 276 
However, for homozygote carriers of 279Phe, Lp-PLA2 activity should be almost abolished across all tissues. 277 
Finally, we studied life-long genetic reductions in Lp-PLA2 activity in relation to first-onset CHD outcomes 278 
rather than recurrent CHD, whereas darapladib trials studied recurrent coronary events in patients with stable or 279 
acute coronary disease.  280 
The current data underscore the growing importance of human genetic approaches to enhance the efficiency of 281 
development of medicines by validating (or invalidating) novel drug targets35-38. Specifically, despite beneficial 282 
effects of darapladib on surrogate markers (e.g. intravascular imaging) of coronary atherosclerosis in pre-clinical 283 
and clinical studies39-41, these effects did not translate into reduced outcomes in the large phase III studies. 284 
Hence, human genetic studies may be useful in influencing prioritization of clinical outcome trials in the future.  285 
Our results also illustrate how human genetic evidence can assist interpretation of observational epidemiological 286 
data. For example, we found that functional alleles in PLA2G7 do not alter levels of pro-atherogenic lipds (eg, 287 
LDL-C), suggesting that such pro-atherogenic lipids do not mediate associations between Lp-PLA2 activity and 288 
CHD and supporting the need to adjust epidemiological associations of Lp-PLA2 activity with CHD risk for pro-289 
atherogenic lipds (an approach which yields results consistent with non-causality)3.  290 
13 
In summary, we found that none of a series of Lp-PLA2–lowering alleles was related to CHD risk, suggesting 291 
that Lp-PLA2 is unlikely to be a causal risk factor in CHD.   292 
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FIGURE LEGENDS 432 
Figure 1: Summary of study design 433 
Figure 2 Mean per allele differences in Lp-PLA2 activity and cardiovascular risk factor levels by Lp-PLA2 434 
lowering alleles or with darapladib 160mg daily 435 
Figure 3: Association of Lp-PLA2-lowering alleles with Lp-PLA2 activity and CHD risk 436 
 437 
19 
APPENDIX 438 
List of authors and affiliations 439 
John M. Gregson* PhD, Daniel F. Freitag* PhD, Praveen Surendran PhD, Cardiovascular 440 
Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, 441 
Cambridge, UK; Nathan O. Stitziel MD PhD, Departments of Medicine and Genetics, Washington 442 
University School of Medicine, St Louis, Missouri 63110, USA; Rajiv Chowdhury MD, Stephen 443 
Burgess PhD, Stephen Kaptoge PhD, Pei Gao PhD, James R. Staley MSc, Cardiovascular 444 
Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, 445 
Cambridge, UK; Peter Willeit MD, PhD, Department of Public Health and Primary Care, University 446 
of Cambridge, Cambridge, UK and Department of Neurology, Innsbruck Medical University, 447 
Innsbruck, Austria; Sune F. Nielsen PhD, Copenhagen University Hospital, University of 448 
Copenhagen, Copenhagen, Denmark; Muriel Caslake PhD, University of Glasgow, Glasgow, UK; 449 
Stella Trompet PhD, Leiden University Medical Center, Leiden, Netherlands; Linda M. Polfus PhD, 450 
University of Texas Health Science Center Houston, TX, USA; Kari Kuulasmaa PhD, Jukka Kontto 451 
MSSc, THL-National Institute for Health and Welfare, Helsinki, Finland; Markus Perola MD, PhD, 452 
Institute of Molecular Medicine FIMM, University of Helsinki and Department of Health, National 453 
Institute for Health and Welfare, Helsinki, Finland; Stefan Blankenberg MD, Department of General 454 
and Interventional Cardiology, University Heart Center Hamburg, Germany and University Medical 455 
Center Hamburg Eppendorf, Hamburg, Germany; Giovanni Veronesi PhD, EPIMED Research 456 
Center, Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy; 457 
Francesco Gianfagna MD, PhD, EPIMED Research Center, Department of Clinical and Experimental 458 
Medicine, University of Insubria, Varese, Italy and Department of Epidemiology and Prevention, 459 
IRCCS Istituto Neurologico Mediterraneo Neuromed, Pozzilli, Italy; Satu Männistö, THL-National 460 
Institute for Health and Welfare, Helsinki, Finland; Akinori Kimura MD, PhD, Department of 461 
Molecular Pathogenesis, Medical Research Institute, Tokyo Medical and Dental University (TMDU), 462 
Tokyo, Japan; Honghuang Lin PhD, Section of Computational Biomedicine, Department of Medicine, 463 
Boston University School of Medicine, Boston, MA, USA and The NHLBI's Framingham Heart 464 
20 
Study, Framingham, MA, USA; Dermot F.Reilly PhD, Merck Research Laboratories, Genetics and 465 
Pharmacogenomics, Boston, Massachusetts, USA; Mathias Gorski, Department of Genetic 466 
Epidemiology, University of Regensburg, Regensburg, Germany and Department of Nephrology, 467 
University Hospital Regensburg, Regensburg, Germany; Vladan Mijatovic on behalf of the CKDGen 468 
consortium, Department of Life and Reproduction Sciences, University of Verona, Verona, Italy; 469 
Patricia B. Munroe PhD, Clinical Pharmacology and The Genome Centre, William Harvey Research 470 
Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of 471 
London, London, UK and NIHR Barts Cardiovascular Biomedical Research Unit, Queen Mary 472 
University of London, London, UK; Georg B. Ehret MD on behalf of the International Consortium for 473 
Blood Pressure;, Center for Complex Disease Genomics, McKusick-Nathans Institute of Genetic 474 
Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA and Cardiology, 475 
Department of Medicine, Geneva University Hospital, Geneva, Switzerland and Institute of Social 476 
and Preventive Medicine (IUMSP), Centre Hospitalier Universitaire Vaudois and University of 477 
Lausanne, Lausanne, Switzerland; Alex Thompson PhD, Strategic Epidemiology NewMedicines, 478 
UCB, Brussels, Belgium; Maria Uria-Nickelsen PhD, Clinical Research, Pfizer Worldwide R&D, 479 
Cambridge, Massachusetts, USA; Anders Malarstig PhD, Clinical Research, Pfizer Worldwide R&D, 480 
Sollentuna, Sweden; Abbas Dehghan MD PhD on behalf of the CHARGE inflammation working 481 
group, Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The 482 
Netherlands; Thomas F. Vogt PhD, Merck Research Laboratories, Cardiometabolic Disease, 483 
Kenilworth, New Jersey, USA and CHDI Management/CHDI Foundation, Princeton, New Jersey, 484 
USA; Taishi Sasaoka MD, PhD, Department of Molecular Pathogenesis, Medical Research Institute, 485 
Tokyo Meidcal and Dental University (TMDU), Tokyo, Japan; Fumihiko Takeuchi PhD, Norihiro 486 
Kato MD, DPhil, Department of Gene Diagnostics and Therapeutics, Research Institute, National 487 
Center for Global Health and Medicine, Japan; Yoshiji Yamada MD, PhD, Department of Human 488 
Functional Genomics, Life Science Research Center, Mie University, Japan; Frank Kee MD, Director, 489 
UKCRC Centre of Excellence for Public Health, Queens, University, Belfast, Ireland; Martina 490 
Müller-Nurasyid PhD, Institute of Genetic Epidemiology, Helmholtz Zentrum München - German 491 
Research Center for Environmental Health, Neuherberg, Germany and Institute of Medical 492 
21 
Informatics, Biometry and Epidemiology, Chair of Genetic Epidemiology, Ludwig-Maximilians-493 
Universität, Munich, Germany and DZHK (German Centre for Cardiovascular Research), partner site 494 
Munich Heart Alliance, Munich, Germany and Department of Medicine I, Ludwig-Maximilians-495 
University Munich, Munich, Germany; Jean Ferrières MD, Department of Epidemiology, UMR 1027- 496 
INSERM, Toulouse University-CHU Toulouse, Toulouse, France; Dominique Arveiler MD, 497 
Department of Epidemiology and Public Health, EA 3430, University of Strasbourg and Strasbourg 498 
University Hospital, Strasbourg, France; Philippe Amouyel MD, Department of Epidemiology and 499 
Public Health,Institut Pasteur de Lille, Lille, France; Veikko Salomaa MD, PhD, THL-National 500 
Institute for Health and Welfare, Helsinki, Finland; Eric Boerwinkle PhD, Human Genetics Center, 501 
University of Texas Health Science Center at Houston, TX, USA; Simon G. Thompson FMedSci, 502 
Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of 503 
Cambridge, Cambridge, UK; Ian Ford PhD, University of Glasgow, Glasgow, UK; J. Wouter Jukema 504 
MD, Leiden University Medical Center, Leiden, Netherlands; Naveed Sattar MD, Chris J. Packard 505 
PhD, University of Glasgow, Glasgow, UK; Abdulla al Shafi Majumder MD, National Institute of 506 
Cardiovascular Diseases, Sher-e-Bangla Nagar, Dhaka, Bangladesh; Dewan S Alam MD, PhD, Centre 507 
for Global Health Research, St. Michael Hospital, Toronto, ON, Canada; Panos Deloukas PhD, 508 
William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen 509 
Mary University of London, London, UK; Heribert Schunkert MD, Deutsches Herzzentrum München, 510 
Technische Universität München, and German Centre for Cardiovascular Research (DZHK), partner 511 
site Munich Heart Alliance, all Munich, Germany; Nilesh J. Samani FMedSci, Department of 512 
Cardiovascular Sciences, University of Leicester and National Institute for Health Research Leicester 513 
Cardiovascular Biomedical Research Unit, Leicester, UK; Sekar Kathiresan MD on behalf of the 514 
MICAD Exome consortium, Broad Institute, Cambridge and Massachusetts General Hospital, Boston, 515 
MA, USA; Børge G. Nordestgaard MD, Copenhagen University Hospital, University of Copenhagen, 516 
Copenhagen, Denmark; Danish Saleheen* MD, University of Pennsylvania, Philadelphia, US and 517 
Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of 518 
Cambridge, Cambridge, UK; Joanna M.M. Howson* PhD, Emanuele Di Angelantonio* MD, Adam 519 
S. Butterworth* PhD, Cardiovascular Epidemiology Unit, Department of Public Health and Primary 520 
22 
Care, University of Cambridge, Cambridge, UK; John Danesh* FMedSci on behalf of the EPIC-CVD 521 
Consortium and the CHD Exome+ Consortium, Cardiovascular Epidemiology Unit, Department of 522 
Public Health and Primary Care, University of Cambridge, Cambridge, UK and Wellcome Trust 523 
Sanger Institute, Hinxton, UK 524 
23 
TABLES 525 
Table 1: Definitions and source of contributing data for the main study outcome 526 
 527 
^ In genetic analysis, CHD was defined as myocardial infarction and other major coronary events (~90% of cases) or angiographic stenosis only (~10% of cases) see eTables 2 & 3 for details. In the darapladib analysis CHD was defined as fatal coronary disease, non-fatal MI or urgent 528 
revascularization for myocardial ischaemia. 529 
$ See eTables 2 & 3 for details on risk factor measurements 530 
*rs142974898 (c.109+2T>C), rs144983904 (Arg82His), rs76863441 (Val279Phe), rs140020965 (Gln287Ter); see also Figure 1B for further variant details; BMI = Body-mass index, eGFR = estimated glomerular filtration rate, NA= Data not available. Further detail on the individual 531 
studies is provided in eTables 2-3.  532 
†Participant level data available 533 
‡ Summary/tabular data available (by study) 534 
§ Meta-analysis data available 535 
CARDIoGRAM=Coronary ARtery DIsease Genome wide Replication and Meta-analysi; CHARGE=Cohorts for Heart and Aging Research in Genomic Epidemiology; CKDGen=Chronic Kidney Disease GENetics consortium; GIANT=Genetic Investigation of ANthropometric Traits 536 
Consortium; GLCC=Global Lipids Genetics Consortium; ICBP=International Consortium for Blood Pressure; MAGIC=Meta-Analyses of Glucose and Insulin-related traits Consortium;  537 
Lp-PLA2 
assessment tool 
Val279Phe, Loss-of-
function variant 
common in East 
Asians 
Four loss-of-function variants*, rare in 
Europeans & South Asians 
Val379Ala, modest impact variant Darapladib 
Data sources Systematic review: Up 
to 12 East Asian 
studies 
De-novo genotyping and participant-level data: up to 8 European or or South Asian ancestry studies from the CHD Exome+ Consortium19-26; 
De-novo genotyping  and study-level data: up to 15 European ancestry studies from the MICAD Exome consortium38 and 3 European ancestry studies from the 
CHARGE Consortium17,29; 
Plus publicly available consortium data   
Systematic review:  
Up to 5 randomized clinical 
trials6,7,39-41 from a systematic 
review 
Endpoint Number of studies and unique individuals contributing to analyses; n total or cases / controls 
Coronary 
heart disease^ 
7 East Asian studies ‡ 8 European or South 
Asian ancestry 
studies from the  
CHD Exome+ 
Consortium19-26 † 
15 European ancestry 
studies from the 
MICAD Exome  
consortium38 ‡ 
8 European or South 
Asian ancestry studies 
from the CHD Exome+  
Consortium19-26 † 
8 European ancestry 
studies from the 
MICAD Exome  
consortium38 ‡ 
14 European ancestry 
studies from the 
CARDIoGRAM 
consortium27 § 
4 European or South Asian 
ancestry studies from the C4D 
consortium28 § 
2 phase III randomized 
clinical trials of darapladib6,7 
‡ 
10,088 cases 
15,199 controls 
35,829 cases 
44,948 controls 
35,533 cases 
64,130 controls 
32,196 cases 
41,464 controls 
14,976 cases 
32,084 controls 
20,315 cases 
58,419 controls 
15,420 cases 
15,062 controls 
3364 cases 
25,490 non-cases 
Lp-PLA2 
activity$ 
12 East Asian studies ‡ 1 European ancestry 
study from the CHD 
Exome+ 
Consortium25 † 
1 European ancestry 
study from the 
CHARGE 
Consortium29 ‡ 
2 European ancestry studies from the CHD 
Exome+ Consortium22,23,25 † 
3 European ancestry studies from the CHARGE 
consortium17 ‡ 
3 phase II randomized 
clinical trials39-41 ‡ 
8468 1240 8564 2173 11,662 854 
Conventional 
risk factors$ 
12 East Asian studies ‡ 8 European or South Asian ancestry studies 
from the CHD Exome+ Consortium19-26 † 
8 European or South Asian ancestry studies from 
the CHD Exome+ Consortium19-26 † 
Publicly available consortium data§ 5 randomized clinical  
trials6,7,39-41 ‡ 
BMI 17,898 76,584 51,201 126,142  from 46 studies from the GIANT Consortium42 NA 
Blood pressure 6705 72,450 71,256 69,245 from 29 studies from the ICBP Consortium43 323 
Lipids 17,643 76,826 55,431 94,311 from 46 studies from the GLGC Consortium44 803 
C-reactive 
protein 
2914 40,484 41,442 66,185 from 15 studies from the CHARGE Consortium45 848 
Glycaemic 
traits 
2914 9420 9408 46,186 from 21 studies from the MAGIC Consortium46 NA 
eGFR 4017 32,929 32,190 74,354 from 26 studies from the CKDGen Consortium47 NA 
24 
 538 
 539 
Table 2: Comparison on a common scale of human genetic and randomized trial evidence for Lp-PLA2 lowering and CHD 540 
 CHD patients Controls Risk ratio for CHD per 65% lower Lp-PLA2 
activity (95% CI) 
Genetically lowered Lp-PLA2    
Val279Phe (East Asian LoF variant) 10,088 15,199 0.95 (0.88 - 1.03) 
Four LoF variants* 71,362 109,078 0.92 (0.74 – 1.16) 
Val379Ala 82,907 147,029 1.01 (0.68 – 1.51) 
    
Pharmacologically lowered Lp-PLA2    
Darapladib 3364 25,490 0.95 (0.89 – 1.02) 
* Carriage of any of the four loss-of-function variants c.109+2T>C, Arg82His; Val279Phe; Gln287Ter; LoF = Loss-of-function 541 
 542 
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Figure 1: Summary of study design 543 
 544 
A) Flow chart of study design B) Exonic structure of the PLA2G7 gene and location of variants used in this study.; ExAc = Exome Aggregation consortium, Lp-PLA2 = Lipoprotein-associated phospholipase A2, RCT = 545 
Randomized controlled trial, UniProt/Swissprot = Manually annotated and reviewed section of the Universal Protein resource database.546 
Genetic inhibition 
of Lp-PLA2
• Four loss-of-function variants
• One missense variant
Soluble Lp-PLA2 activity
Coronary disease events
Conventional cardiovascular 
risk factors (eg, lipids)
UniProt/Swissprot database
1000 Genomes project
Exome sequencing project
ExAc consortium
Results from de-novo genotyping, global 
consortia and systematic literature reviews
Pharmacological 
inhibition of Lp-PLA2
• Darapladib (160mg)
Systematic review of RCTs 
A
B PLA2G7 gene coding exons 
1 2 3 4 5 6 7 8 9 10 11
rs144983904 
Arg82His
rs76863441 
Val279Phe 
rs140020965 
Gln287Ter
rs1051931 
Val379Ala
Loss-of-function variants Modest impact variant
26 
Figure 2  547 
 548 
To enable comparison of the magnitude of associations across several different markers, analyses were undertaken with standardized units of measurement for each marker. Associations are presented as per allele 549 
change in the biomarker expressed as standard deviations. * Carriage of any of the four loss-of-function variants c.109+2T>C, Arg82His; Val279Phe; Gln287Ter; BMI = Body-mass index, DBP = Diastolic blood 550 
pressure, eGFR = estimated glomerular filtration rate, HDL-c = High-density lipoprotein cholesterol, LDL = low-density lipoprotein cholesterol, LoF = Loss-of-function, Lp-PLA2 = Lipoprotein associated 551 
phospholipase A2, SBP = systolic blood pressure. Numbers of participants are provided in Table 1. Details of contributing studies are provided in eTables 2-3.552 
Lp-PLA2 activity
BMI
SBP
DBP
LDL-c
HDL-c
Triglycerides
C-reactive protein
Glucose
eGFR
Trait
<10-300
0.92
0.94
0.48
0.14
0.22
0.35
0.43
0.45
0.31
P-value
0-3 -2 -1 1
Lp-PLA2 activity
BMI
SBP
DBP
LDL-c
HDL-c
Triglycerides
C-reactive protein
Glucose
Insulin
eGFR
Trait
1.64x10-25
0.54
0.96
0.81
0.25
0.77
0.99
0.38
0.48
0.85
0.44
P-value
0-3 -2 -1 1
Lp-PLA2 activity
BMI
SBP
DBP
LDL-c
HDL-c
Triglycerides
C-reactive protein
Glucose
Insulin
eGFR
Trait
1.89x10-12
0.19
1.00
0.55
0.87
0.04
0.85
0.74
0.88
0.65
0.27
P-value
0-3 -2 -1 1
Lp-PLA2 activity
SBP
LDL-c
HDL-c
Triglycerides
C-reactive protein
Trait
0.03
0.84
0.04
0.57
0.05
P-value
<10-300
0-3 -2 -1 1
Standardized mean difference per allele (95 % CI)
Standardized mean difference per loss of function allele (95 % CI)Standardized mean difference per loss of function allele (95 % CI)
Standardized mean difference per 160mg darapladib (95 % CI)
Four LoF variants combined*Val279Phe (LoF)
Val379Ala Darapladib 160mg daily
27 
Figure 3 553 
 554 
Spectrum of functional alleles in PLA2G7 and effects on Lp-PLA2 activity (red estimates) and coronary heart disease risk (black estimates); * Carriage of any of the four loss-of-function variants c.109+2T>C, 555 
Arg82His; Val279Phe; Gln287Ter; † One study did not provide tabular data to enable calculation of CHD odds ratios in heterozygotes or homozygotes. Hence, numbers are less than those presented for the per allele 556 
analysis in Table 2; LoF = Loss-of-function 557 
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